The once-daily product features a nested capsule-in-capsule technology as well as clinically studied doses of Ceratiq ceramides and Hyabest hyaluronic acid.
MoCRA expands FDA’s authority over cosmetics with requirements for safety substantiation, adverse event reporting, facility registration, and product listing.
By Evelina J. Norwinski, Elizabeth Trentacost, and Ryan D. White, Arnold & Porter 04.13.23